The EPS beat and raised guidance, combined with the debt repayment, signal strong operational momentum and improving financial health. The stock should react positively. Key catalysts to watch: continued LINZESS prescription demand growth and enrollment updates for the STARS-2 apraglutide trial.
Price Chart
Executive Summary
Ironwood Pharmaceuticals reported Q2 2026 GAAP EPS of $0.31, beating the $0.28 consensus by 10.7%, on revenue of $113.0M (slightly below the $114.7M estimate). The company raised full-year 2026 guidance: LINZESS U.S. net sales to $1.15-$1.20B (from $1.125-$1.175B), total revenue to $460-$485M (from $450-$475M), and adjusted EBITDA to >$310M (from >$300M). The beat was driven by strong LINZESS performance (14% YoY net sales growth, 78% commercial margin) and the company repaid its $200M convertible notes with cash on hand, strengthening the balance sheet. The STARS-2 Phase 3 trial for apraglutide is now actively recruiting patients.
Key Financial Metrics
Key Facts
- GAAP EPS of $0.31 beat consensus of $0.28 by 10.7%
- Total revenue of $113.0M vs consensus of $114.7M (slight miss)
- LINZESS U.S. net sales of $282.3M, up 14% YoY
- Full-year 2026 guidance raised: LINZESS net sales to $1.15-$1.20B, total revenue to $460-$485M, adjusted EBITDA >$310M
- Repaid $200M convertible notes in full with cash on hand
- STARS-2 confirmatory Phase 3 trial for apraglutide now actively recruiting patients
- GAAP net income of $51.3M vs $23.6M in Q2 2025
- Adjusted EBITDA of $83.0M vs $50.1M in Q2 2025
- Cash from operations of $58.3M vs $15.1M in Q2 2025
Financial Impact
EPS beat of $0.03 (10.7%) on consensus of $0.28; revenue slightly below consensus by $1.7M (1.5%). Full-year guidance raised by $25M on LINZESS net sales and $10M on total revenue.
Risk Factors
- LINZESS net price improvement may not be sustainable if gross-to-net rebate timing normalizes
- Apraglutide STARS-2 trial carries clinical and regulatory risk
- High leverage ($385M revolver) despite debt repayment
- Cash balance dropped to $79.1M from $215.5M at year-end 2025 due to debt repayment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-091625 |
| Document: tm2622244d1_8k.htm | 0001104659-26-091625 |
| Document: 0001104659-26-091625-index-headers.html | 0001104659-26-091625 |
| Document: 0001104659-26-091625-index.html | 0001104659-26-091625 |
| Document: 0001104659-26-091625.txt | 0001104659-26-091625 |
| 8-K Data (Synthetic) | 0001104659-26-091625 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $4.26 $4.29 | ▲ +0.70% | ▲ +0.10% | $3.62 (−15.02%) |
May 13, 2026 20w ago | 8-K | $3.68 $3.63 | ▼ −1.36% | ▼ −0.75% | $3.62 (−1.63%) |
May 7, 2026 21w ago | 8-K | $4.17 $3.24 | ▼ −22.30% | ▼ −25.44% | $3.62 (−13.19%) |
Feb 25, 2026 31w ago | 8-K | $3.36 $3.19 | ▲ +5.06% | ▼ −0.18% | $3.62 (−7.74%) |
Feb 23, 2026 31w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.62 (+3.47%) |
Feb 23, 2026 31w ago | Insider Cluster | $3.75 $3.29 | ▲ +12.27% | ▲ +8.32% | $3.62 (+3.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access